MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF

Cancer Genetics

Volumn 205, Issue 11, 2012, Pages 545-551

  Mosakhani, Neda ^a   Lahti, Leo ^b   Borze, Ioana ^a   Karjalainen Lindsberg, Marja Liisa ^a   Sundström, Jari ^c   Ristamäki, Raija ^c   österlund, Pia ^a   Knuutila, Sakari ^a   Sarhadi, Virinder Kaur ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Anti EGFR treatment; Colorectal cancer; MiRNA; Wild type BRAF; Wild type KRAS

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; LET 7; MESSENGER RNA; MICRORNA; MICRORNA 1224 5P; MICRORNA 140 5P; MICRORNA 31; MICRORNA 592; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATN1 GENE; BRAF GENE; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL ARTICLE; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC26A3 GENE; SURVIVAL PREDICTION; UPREGULATION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHLORIDE-BICARBONATE ANTIPORTERS; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84869406102     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.08.003     Document Type: Article

References (34)

1. Vale C.L., Tierney J.F., Fisher D., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012, 38:618-625.
2. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
3. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
4. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
5. Heinemann V., Stintzing S., Kirchner T., et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009, 35:262-271.
6. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
7. Tveit K., Guren T., Glimelius B., et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group [abstract]. J Clin Oncol 2011, 29. (suppl 4; abstr 365).
8. Mattie M.D., Benz C.C., Bowers J., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
9. Lebanony D., Benjamin H., Gilad S., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037.
10. Rukov J.L., Shomron N. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 2011, 17:412-423.
11. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
12. Monzo M., Navarro A., Bandres E., et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008, 18:823-833.
13. Earle J.S., Luthra R., Romans A., et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010, 12:433-440.
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Frattini M., Balestra D., Suardi S., et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004, 10:4015-4021.
16. Mosakhani N., Guled M., Lahti L., et al. Unique microRNA profile in Dupuytren's contracture supports deregulation of β-catenin pathway. Mod Pathol 2010, 23:1544-1552.
17. Spitzner M., Emons G., Kramer F., et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 2010, 78:1184-1192.
18. Baker J.B., Dutta D., Watson D., et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011, 104:488-495.
19. Mlakar V., Berginc G., Volavsek M., et al. Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. BMC Cancer 2009, 9:282.
20. Sarver A.L., French A.J., Borralho P.M., et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009, 9:401.
21. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
22. Drummond J.T., Anthoney A., Brown R., et al. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271:19645-19648.
23. Silva J., Garcia V., Zaballos A., et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011, 37:617-623.
24. Zuo Z., Calin G.A., de Paula H.M., et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011, 118:413-415.
25. Ali S., Almhanna K., Chen W., et al. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010, 3:28-47.
26. Song B., Wang Y., Xi Y., et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
27. Malzkorn B., Wolter M., Liesenberg F., et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2010, 20:539-550.
28. Tardif G., Hum D., Pelletier J.P., et al. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord 2009, 10:148.
29. Shersher D.D., Vercillo M.S., Fhied C., et al. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg 2011, 92:1805-1811.
30. Ahn B.Y., Elwi A.N., Lee B., et al. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 2010, 70:3013-3019.
31. Dudziec E., Miah S., Choudhry H.M., et al. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011, 17:1287-1296.
32. Niu Y., Mo D., Qin L., et al. Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-α gene expression by modulating Sp1. Immunology 2011, 133:8-20.
33. Puvvada S.D., Funkhouser W.K., Greene K., et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010, 78:181-188.
34. Scartozzi M., Bearzi I., Pierantoni C., et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007, 25:3930-3935.